Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is intensifying its commitment to the country with a total investment of EUR 1.3 billion its new global R&D hub in Barcelona. Spain is a…
While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that neighbouring Spain has made as…
The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI) by 38 percent and NASDAQ Biotech by 46 per cent between 2015 and 2020. Key listings include Kuros Biosciences, Idorsia, Polyphor, ObsEva, and IGEA Pharma Made with Visme Infographic Maker To read more about the Swiss biotech investment ecosystem, see our interview with…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its pipeline. With an FDA green light for its 2017-acquired Onivyde and an expected approval for its Genfit-partnered therapy this year, the strategy looks to be…